source
- BMS drops Orum’s targeted degrader after Phase 1 resultsBMS announced it is ending development of ORM-6151, a degrader‑antibody conjugate acquired from Orum Therapeutics. The decision follows a Phase 1 trial in acute myeloid leukemia and myelodysplasti…
- Biopharma prediction markets raise insider-info concerns, regulators weigh oversightPrediction markets are emerging as platforms where participants can wager on biopharma events such as clinical trial results and FDA approvals. The format allows crowds to aggregate expectations ab…